Intellia Therapeutics, Inc. NTLA
11.75
(0.41)
(3.37%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow NTLA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
33.08 | 14.40 | 22.98 | 37.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.75) | (14.06) | (12.94) | (27.17) | |
P/B ratio |
2.54 | 1.45 | 2.45 | 3.10 | |
Price to Tangible BV |
2.54 | 1.45 | 2.45 | 3.10 | |
EV/Sales |
24.20 | 7.75 | 17.29 | 30.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.39) | (1.33) | (3.15) | (5.25) | |
EV/FCF |
(3.37) | (1.32) | (3.14) | (5.22) | |
Quick Ratio |
5.57 | 4.42 | 5.04 | 5.61 | |
Current Ratio |
6.21 | 5.08 | 6.10 | 6.65 | |
Net Debt/EBITDA |
4.80 | 4.85 | 3.82 | 3.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.07 | 0.08 | 0.07 | |
Operating CF/Net income |
0.76 | 0.72 | 1.22 | 0.78 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.04) | (0.83) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
687.47% | 385.16% | 536.53% | 1,078.40% | |
Selling, General and Administrative Expense of Revenue |
221.39% | 143.70% | 231.55% | 493.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
142.24% | 72.72% | 89.57% | 236.00% | |
Graham Net Nets |
0.21 | 0.37 | 0.22 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.72%) | (42.60%) | (27.61%) | (19.86%) | |
Free Cash Flow Yield |
(21.68%) | (40.63%) | (23.94%) | (15.43%) | |
Revenue per Share |
0.13 | 0.21 | 0.13 | 0.06 | |
Operating CF per Share |
(0.70) | (0.64) | (0.99) | (0.62) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.70) | (0.64) | (0.99) | (0.64) | |
Cash per Share |
4.64 | 4.15 | 3.17 | 3.28 | |
Shareholders Equity per Share |
6.79 | 6.20 | 5.24 | 5.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.79 | 6.20 | 5.24 | 5.45 | |
Free Cash Flow |
(76.93) | (69.41) | (117.42) | (84.83) | |
Working Capital |
488.22 | 423.83 | 390.00 | 448.44 | |
Capital Expenditures |
(0.03) | (0.13) | (0.08) | (1.72) | |
Net Current Asset Value |
405.09 | 356.98 | 328.61 | 398.37 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.22 | |
Net Profit Margin |
(735.19%) | (416.15%) | (639.49%) | (1,392.27%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.95 | 8.99 | 9.82 | 9.34 | |
Average Payables |
13.20 | 17.42 | 15.58 | 10.76 | |
Average Assets |
1,049.31 | 1,016.57 | 872.47 | 878.03 | |
Average Common Equity |
855.52 | 771.68 | 700.43 | 721.48 |
Columns are period end dates